Bullish & Foolish
Full XFOR fundamentals All 466 on the Survival Watch

XFORX4 PHARMACEUTICALS, INC

Is X4 Pharmaceuticals struggling financially?

Yes, by its own account. X4 Pharmaceuticals told the SEC on 17 Mar 2026, in Form 10-K, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Mar 2026

30/100

Fragile

Cries for help

  • Needs to raise money

    Until we reach profitability, we will need to raise additional capital, which cannot be assured, to fund our operations and meet our financial obligations beyond this period.

    Form 10-Q, filed 6 May 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$400.6M
Source filing
10-K 17 Mar 2026
Balance sheet
30 Jun 2026

Cash runway

  • 23months

    If the burn speeds up

    Empty by May 2028

  • 32months

    If it eases off

    Empty by Mar 2029

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$195.1M

÷

Cash burned over the last 12 months

$86.1M

What X4 Pharmaceuticals told the SEC

…profitability, our operations will require substantial additional funding. Our history of recurring losses and anticipated future expenditures could raise substantial doubts about our ability to continue as a going concern. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate any product development programs or commercialization efforts. We have incurred…

X4 PHARMACEUTICALS, INC, Form 10-K, filed 17 Mar 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 1680.1% share-count increase The company issued stock. Each share now owns 94.4% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 54% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt